EPI-326

EpiBiologics · Phase 1 active Small molecule

At a glance

Generic name	EPI-326
Also known as	EPI-326 Injection
Sponsor	EpiBiologics
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EPI-326 CI brief — competitive landscape report
EPI-326 updates RSS · CI watch RSS
EpiBiologics portfolio CI